Trial of Solanezumab in Preclinical Alzheimer’s Disease
Abstract: Trials of monoclonal antibodies that target various forms of amyloid at different stages of Alzheimer’s disease have had mixed results.
Read more: https://www.nejm.org/doi/full/10.1056/NEJMoa2305032
